Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
BM (Hons) FRCP DM
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral.
Moccia M. et al, (2019), Ann Neurol
Demographic, clinical and paraclinical features in a subgroup of patients with neuromyelitis optica spectrum disorder
Wegehaupt T. et al, (2019), EUROPEAN JOURNAL OF NEUROLOGY, 26, 870 - 870
Efficacy of satralizumab (SA237) as add-on therapy in pre-specified additional analyses of SAkuraSky, a double-blind placebo-controlled Phase 3 study in patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)
Yamamura T. et al, (2019), EUROPEAN JOURNAL OF NEUROLOGY, 26, 108 - 108
Paediatric myasthenia gravis: any prognostic factor for disease remission?
Vecchio D. et al, (2019), EUROPEAN JOURNAL OF NEUROLOGY, 26, 94 - 94
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
Juryńczyk M. et al, (2019), Practical Neurology, 19, 187 - 195